Aldeyra Therapeutics/$ALDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Ticker
$ALDX
Sector
Primary listing
Employees
7
Headquarters
Website
ALDX Metrics
BasicAdvanced
$118m
-
-$0.45
1.15
-
Price and volume
Market cap
$118m
Beta
1.15
52-week high
$6.18
52-week low
$1.07
Average daily volume
1m
Financial strength
Current ratio
2.724
Quick ratio
2.672
Total debt to equity
36.798
Interest coverage (TTM)
-15.01%
Profitability
EBITDA (TTM)
-28.127
Management effectiveness
Return on assets (TTM)
-22.22%
Return on equity (TTM)
-51.76%
Valuation
Price to book
2.8
Price to tangible book (TTM)
2.8
Price to free cash flow (TTM)
-4.538
Free cash flow yield (TTM)
-22.04%
Free cash flow per share (TTM)
-0.432
Growth
Earnings per share change (TTM)
-53.01%
3-year earnings per share growth (CAGR)
-24.08%
10-year earnings per share growth (CAGR)
-11.75%
What the Analysts think about ALDX
Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.
ALDX Financial Performance
Revenues and expenses
ALDX Earnings Performance
Company profitability
ALDX News
AllArticlesVideos
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Business Wire·1 week ago
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
MarketBeat·2 weeks ago
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs